Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,373 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle (Placebo Comparator) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants

NCT04882631
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PBI-100 Topical Cream, Positive Control - Sodium laurel sulfate (SLS), PBI-100 Topical Cream, Vehicle, Negative Control
Drug · Other
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Newtown Square, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Patients With Intermittent Claudication Injected With ALDH Bright Cells

NCT01774097
View directory record Official record
Conditions
Peripheral Artery Disease, Intermittent Claudication
Interventions
ALD-301, Placebo (vehicle)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 3 Interventional

BE Study of Naftifine HCL

NCT02633813
View directory record Official record
Conditions
Tinea Pedis
Interventions
Naftifine hydrochloride 2%, Placebo, Naftin® 2% (Naftifine hydrochloride 2%)
Drug
Lead sponsor
Genzum Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
693 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
12
States / cities
Brandon, Florida • Miami, Florida • Miramar, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

NCT03393494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene and Benzoyl Peroxide Topical Gel, Epiduo Topical Product, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Trial II of Lung Protection With Azithromycin in the Preterm Infant

NCT00319956
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
Hubert Ballard
Other
Eligibility
Up to 72 Hours
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Assess Subjects With Dry Eye Disease.

NCT04971031
View directory record Official record
Conditions
Dry Eye
Interventions
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 7, 2026, 4:13 AM EDT
Terminated Phase 2 Interventional Results available

Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest

NCT03079102
View directory record Official record
Conditions
Heart Arrest, Out-Of-Hospital
Interventions
Nitric Oxide, Nitrogen
Drug
Lead sponsor
Cameron Dezfulian
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
McKeesport, Pennsylvania • Monroeville, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 4 Interventional

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

NCT05514041
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Varenicline solution, Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Drug
Lead sponsor
Stephenson Eye Associates
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Venice, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 1 Interventional

A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI

NCT02723539
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
MBN-101, Placebo
Drug
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Fresno, California • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis

NCT01878461
View directory record Official record
Conditions
Psoriasis
Interventions
Vehicle, M518101
Drug
Lead sponsor
Maruho North America Inc.
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
34
States / cities
Mesa, Arizona • Encino, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

NCT04598269
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ATI-1777, Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Scottsdale, Arizona • Encino, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 7, 2026, 4:13 AM EDT
Terminated Phase 2 Interventional Results available

A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

NCT04806503
View directory record Official record
Conditions
Presbyopia
Interventions
UNR844, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 55 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Laguna Hills, California • Newport Beach, California • Largo, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

A Study of RX-10045 in the Treatment of Dry Eye Disease

NCT01675570
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RX-10045, Vehicle for RX-10045
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

A Study of DER 45-EV Gel to Treat Rosacea

NCT00940992
View directory record Official record
Conditions
Rosacea
Interventions
DER 45 EV, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Miami, Florida • Augusta, Georgia • Fridley, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

NCT01984775
View directory record Official record
Conditions
Psoriasis
Interventions
GSK2894512 cream, Vehicle cream, Positive control, Negative control
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Topical Cyclosporine Suspension for the Treatment of Brittle Nails

NCT01064830
View directory record Official record
Conditions
Brittle Nail Syndrome
Interventions
topical cyclosporine ophthalmic suspension 0.05%, vehicle
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00287521
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle, Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

NCT01678963
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Squalamine lactate, Vehicle control
Drug
Lead sponsor
Ohr Pharmaceutical Inc.
Industry
Eligibility
50 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
20
States / cities
Tucson, Arizona • Bakersfield, California • Beverly Hilss, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation

NCT00528021
View directory record Official record
Conditions
Pediculus Humanus Capitis, Head Lice
Interventions
Placebo, BGC20-0582
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
2 Years to 70 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Florida City, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03292809
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Newport Beach, California • Torrance, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 7, 2026, 4:13 AM EDT
Terminated Phase 2 Interventional Results available

A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

NCT03738800
View directory record Official record
Conditions
Lamellar Ichthyosis
Interventions
CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
San Diego, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

NCT03064438
View directory record Official record
Conditions
Acne Rosacea
Interventions
ACCU-D1, Vehicle
Drug
Lead sponsor
Accuitis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Louisville, Kentucky • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris

NCT00525499
View directory record Official record
Conditions
Acne Vulgaris
Interventions
ASC-J9 cream, placebo
Drug
Lead sponsor
AndroScience Corp
Industry
Eligibility
12 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Fremont, California • San Diego, California • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 7, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Results available

Combination Therapy for Atopic Dermatitis

NCT00119158
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Combination of pimecrolimus and fluticasone, pimecrolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 7, 2026, 4:13 AM EDT